Real-World Data with CDK4/6 Inhibitors-A Single Center Experience from Croatia.

There was no difference in OS based on the choice of CDK4/6 inhibitor ( p = 0.44) or the adjuvant hormonal therapy ( p = 0.12), although a nonsignificant trend for better OS with ribociclib was present for both regardless of whether it was in first- or second/later-line therapies ( p > 0.05).

also in 5,406 other papers

There was a trend toward a longer PFS (HR 0.57, 95% CI 0.15–2.1) and OS (HR 0.68 (95% CI 0.13–3.41) favoring alpelisib; however, both values did not reach statistical significance ( p = 0.41 and p = 0.65, respectively) ( Table 15 ).

also in 111,027 other papers